Valcyte (Valganciclovir HCl) Patent Expiration, LOE Window & CMS Spending

Valcyte (Valganciclovir HCl) by Cheplapharm Arzneimittel Gmbh: FDA Orange Book LOE 2027-12-11, 8 AB generics, $567K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCheplapharm Arzneimittel Gmbh
FDA Application & PathwayN022257 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-12-11
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$567K
2024 Medicare Part D Spend$85K
2024 Medicaid Spend$482K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel